Verve PCSK9-inhibitor gene therapy
Tracked across 2 events · 18 articles · First seen May 26, 2026 · Last active Sep 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Verve PCSK9-inhibitor gene therapy>>> developed VERVE-102, a groundbreaking gene-editing therapy for high cholesterol. The positive results from its Phase 1b clinical trial are a major success for the company, potentially leading to a new era in cardiovascular disease prevention.
May 26, 2026 · 12 articles
Business
Impact: Acquired by Lilly; part of pipeline investment strategy.
Aug 23, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Verve PCSK9-inhibitor gene therapy live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard